Hepatic safety of antibiotics used in primary care.
J Antimicrob Chemother. 2011 May 17;
Authors: Andrade RJ, Tulkens PM
Antibiotics used by general practitioners frequently appear in adverse-event reports of drug-indu…

[Read more →]

Changing needs of community-acquired bacterial pneumonia: experience with ceftaroline fosamil. Preface.
J Antimicrob Chemother. 2011 Apr;66 Suppl 3:iii1
Authors: Johnson AP, Leibovici L

PMID: 21548186 [PubMed …

[Read more →]

Clinical activity of anti-Gram-positive agents against methicillin-resistant Staphylococcus aureus.
J Antimicrob Chemother. 2011 May;66 Suppl 4:iv17-iv21
Authors: Gould IM
Current concerns about multiresistance and a d…

[Read more →]

Linezolid: safety and efficacy in special populations.
J Antimicrob Chemother. 2011 May;66 Suppl 4:iv3-iv6
Authors: Gould FK
Linezolid has been in general use in the UK since 2000. Although toxicity, particularly haema…

[Read more →]

Ceftaroline fosamil: a new broad-spectrum cephalosporin.
J Antimicrob Chemother. 2011 Apr;66 Suppl 3:iii11-iii18
Authors: Laudano JB
Ceftaroline fosamil, the prodrug of the active metabolite, ceftaroline, is a new, bro…

[Read more →]

Changing needs of community-acquired pneumonia.
J Antimicrob Chemother. 2011 Apr;66 Suppl 3:iii3-iii9
Authors: Ramirez JA, Anzueto AR
Community-acquired pneumonia (CAP) is a serious condition associated with significan…

[Read more →]

Comparative ceftaroline activity tested against pathogens associated with community-acquired pneumonia: results from an international surveillance study.
J Antimicrob Chemother. 2011 Apr;66 Suppl 3:iii69-iii80
Authors: Jones R…

[Read more →]

Is cefepime safe for clinical use? A Bayesian viewpoint.
J Antimicrob Chemother. 2011 Apr 6;
Authors: Kalil AC
Cefepime hydrochloride is approved for pneumonia, empirical therapy for febrile neutropenia, uncomplicated …

[Read more →]

Ceftaroline pharmacodynamic activity versus community-associated and healthcare-associated methicillin-resistant Staphylococcus aureus, heteroresistant vancomycin-intermediate S. aureus, vancomycin-intermediate S. aureus and vancomycin-resista…

[Read more →]

Correlation between antibiotic consumption and resistance of Gram-negative bacteria causing healthcare-associated infections at a university hospital in Taiwan from 2000 to 2009.
J Antimicrob Chemother. 2011 Mar 24;
Authors: L…

[Read more →]

Early versus late oseltamivir treatment in severely ill patients with 2009 pandemic influenza A (H1N1): speed is life.
J Antimicrob Chemother. 2011 Mar 15;
Authors: Kumar A
The need for early antimicrobial therapy is w…

[Read more →]

Pharmacokinetics and safety of panobacumab: specific adjunctive immunotherapy in critical patients with nosocomial Pseudomonas aeruginosa O11 pneumonia.
J Antimicrob Chemother. 2011 Mar 10;
Authors: Lu Q, Rouby JJ, Laterre PF,…

[Read more →]

Surviving the first hours in sepsis: getting the basics right (an intensivist’s perspective).
J Antimicrob Chemother. 2011 Apr;66 Suppl 2:ii11-ii23
Authors: Daniels R
Severe sepsis is a major cause of morbidity and mor…

[Read more →]

Antibiotic dosing in critical illness.
J Antimicrob Chemother. 2011 Apr;66 Suppl 2:ii25-ii31
Authors: McKenzie C
Early and effective antibiotic therapy is essential in the management of infection in critical illness. T…

[Read more →]

Diagnostic and prognostic biomarkers of sepsis in critical care.
J Antimicrob Chemother. 2011 Apr;66 Suppl 2:ii33-ii40
Authors: Kibe S, Adams K, Barlow G
Sepsis is a leading cause of mortality in critically ill patient…

[Read more →]